Regeneron Announces Positive Phase 3 Results For EYLEA HD In Retinal Vein Occlusion Treatment

(RTTNews) – Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating macular edema due to retinal vein occlusion (RVO). This includes patients with centra

Source link